NEW YORK (GenomeWeb) – Personalis has raised $33 million in a Series C financing round, bringing the total amount of venture capital raised to date to $75 million.
Lightspeed Venture Partners was the lead investor in the new round. It was joined by all Series A investors, including Abingworth and Mohr Davidow Ventures.
Menlo Park, Calif.-based Personalis plans to use the new funding to scale up its operations. "With a broadening customer base and strong repeat orders, this additional capital will be important for driving our rapid and continued expansion," CEO John West said in a statement.
Last fall, Personalis launched cancer genome analysis services — the ACE Exome for Cancer and the ACE Extended Cancer Panel — and updated its existing ACE Clinical Exome test for inherited diseases.
"We have had a very positive response to our new offerings in cancer genomics, especially from pharmaceutical customers, and our Mendelian genetic testing business continues to grow," West said.